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E-mail address: awright5@partners.org (A. WrightBackground: The patient problem list is an important component of clinical medicine. The problem list
enables decision support and quality measurement, and evidence suggests that patients with accurate
and complete problem lists may have better outcomes. However, the problem list is often incomplete.
Objective: To determine whether association rule mining, a data mining technique, has utility for identi-
fying associations between medications, laboratory results and problems. Such associations may be use-
ful for identifying probable gaps in the problem list.
Design: Association rule mining was performed on structured electronic health record data for a sample
of 100,000 patients receiving care at the Brigham and Women’s Hospital, Boston, MA. The dataset
included 272,749 coded problems, 442,658 medications and 11,801,068 laboratory results.
Measurements: Candidate medication-problem and laboratory-problem associations were generated
using support, conﬁdence, chi square, interest, and conviction statistics. High-scoring candidate pairs
were compared to a gold standard: the Lexi-Comp drug reference database for medications and Mosby’s
Diagnostic and Laboratory Test Reference for laboratory results.
Results: We were able to successfully identify a large number of clinically accurate associations. A high
proportion of high-scoring associations were adjudged clinically accurate when evaluated against the
gold standard (89.2% for medications with the best-performing statistic, chi square, and 55.6% for labo-
ratory results using interest).
Conclusion: Association rule mining appears to be a useful tool for identifying clinically accurate associ-
ations between medications, laboratory results and problems and has several important advantages over
alternative knowledge-based approaches.
 2010 Elsevier Inc. All rights reserved.1. Introduction
Many applications in biomedical informatics require clinical
knowledge bases, e.g. relating signs and symptoms to diseases
(for automated diagnosis), screening tests and indications (for pre-
ventive care decision support) or diseases and medications (for
indication-based prescribing). These knowledge bases are often
developed and maintained by experts, at signiﬁcant cost. However,
automated methods (usually statistical) for developing such
knowledge bases hold promise. In this paper, we describe a set of
data mining techniques which can be used to automatically infer
(and measure the strength of) relationships between medications,
laboratory results and problems, and validate a knowledge base well rights reserved.
edicine and Primary Care,
School, 1620 Tremont Street,
4; fax: +617 732 7072.
).developed using the technique against two gold standards. We also
describe a particular potential application of this knowledge base:
closing ‘‘gaps” in patient problem lists.2. Background
2.1. Clinical problem lists
Electronic and paper medical records have long been organized
into a variety of sections such as visit notes, medication lists, lab-
oratory results and problem lists. The problem list has been a stan-
dard part of the medical record for a considerable period of time,
but it began to occupy a central place in the diagnostic reasoning
process with Larry Weed’s seminal 1968 paper ‘‘Medical Records
that Guide and Teach”, which introduced the concept of the prob-
lem-orient medical record (POMR) [1] and the ability to create and
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the Certiﬁcation Commission for Health Information Technology
(CCHIT) for all certiﬁed electronic health record (EHR) systems [2]
The problem list is important for a variety of reasons. First, hav-
ing an accurate problem list enables clinicians to see the full spec-
trum of a patient’s problems and is a key input to diagnostic
reasoning. The problem list is also a communication tool – when
a physician is seeing a patient for the ﬁrst time (perhaps in a con-
sultation or while providing coverage for the patient’s regular phy-
sician), the problem list allows him or her to understand the
patient’s issues. Evidence suggests that patients with complete
problems lists may receive higher quality care than patients with
gaps in their problem list [3].
In addition to the apparent direct clinical beneﬁts of a complete
problem list, the problem list has a number of important ancillary
beneﬁts. Clinical decision support systems often depend on coded
data elements, and one study found that 22.3% of decision support
rules at Partners HealthCare depended on problems [4]. An accu-
rate, complete, coded problem list is also critical for quality mea-
surement and research.
Although the problem list is important, there is also substantial
evidence to suggest that it is often woefully incomplete. A study by
Szeto et al. found that among patients with coronary artery disease,
only 49% had the problem on their problem list (accuracy ranged
from 42% for benign prostate hypertrophy to 81% for diabetes) [5].
Szeto also studied the speciﬁcity of problems, and found that it
wasextremelyhigh:98–100%of patientswithaproblemon their list
actually had the problem, suggesting that false positives are low.
2.2. Inferring clinical problems
Because gaps in the problem list are common, researchers have
explored methods for automatically inferring problems. These ef-
forts have principally fallen into two categories: proxy methods
and natural language processing (NLP)-based methods. Proxy
methods attempt to use other clinical data in the EHR to infer prob-
lems. Burton and Simonitas described an approach for inferring
problems from medications in EHRs based on drug indication data
found in the NDF-RT, a standard drug terminology [6]. Carpenter
described a similar system which used expert-developed rules to
locate potential drug-problem mismatches in diabetes [7]. Lin
and Haug described a more sophisticated system based on Bayes-
ian networks [8]; the Lin system focused on ﬁve speciﬁc diagnoses
and used a knowledge base of clinical variable-diagnosis associa-
tions derived from internal medicine text books, but tuned the
algorithm using Bayesian networks.
Proxy methods that use administrative (e.g., claims) data have
also been proposed. Poissant et al. used medication claims from a
Canadian provincial insurance system coupled with an expert-
developed knowledge base of single-indication drugs to identify
problem list gaps with some good success [9].
In addition to proxy methods, a variety of NLP-based methods
have also been proposed. Such systems extract candidate problems
from unstructured clinical text, such as progress notes. Meystre
andHaugdescribedanNLP-based system,using theNational Library
ofMedicine’sMetaMap Transfer application [10] and NegEx [11] for
negation detection that focused on 80 speciﬁc medical problems
[12,13]. They reported an initial precision of 0.756 and recall of
0.740. By customizing theMetaMapdictionary, theywere able to in-
crease their recall to 0.896 with only a slight recall tradeoff. Similar
systems have been described using other NLP engines [14].
2.3. Developing a knowledge base using automated techniques
Building on this prior work, we explored and developed data
mining techniques to automatically identify associations betweenproblems and structured non-problem data in the EHR (medica-
tions and lab results in this analysis). Our goal was to develop a
knowledge base of medication-problem and laboratory result-
problem associations in an automated fashion using data mining
techniques, and to evaluate it. This knowledge base would have a
variety of applications, foremost among them inferring clinical
problems.
The data mining techniques that we used, frequent item set
mining and association rule mining [15] are not themselves novel.
The techniques have been developed in computer science for over
a decade and have been used in a variety of ﬁelds [16–18]. Associ-
ation rule mining underpins Amazon’s recommendation feature,
which suggests books based on the tastes of others whose past
purchase history is similar to yours [19]. We describe frequent
item set mining and association rule mining, and our extensions
to them, in detail in Section 3.
Association rule mining and related techniques have been used
previously in medical informatics. Cao et al. used NLP and co-
occurrence statistics to discover disease-ﬁnding co-occurrences
in discharge summaries with strong results [20]. Wang et al. used
similar techniques to locate potentially unknown adverse effects of
drugs [21], Mullins et al. used the techniques for public health sur-
veillance [22] and several other applications have also been re-
ported in the literature [23,24]. The authors of this paper have
also previously used association rule mining to analyze clinical
information system log ﬁles [25], locate disease-drug associations
in the biomedical literature and clinical text [26] and develop order
sets and corollary orders in an automated fashion [27].
2.4. Hypothesis
We hypothesize that association rule mining will be a feasible
technique for analyzing a large clinical data set to successfully
identify clinically accurate and meaningful associations between
structured data elements (speciﬁcally medications and laboratory
results) and problems in the EHR. We also hypothesize that the
cost of generating such associations through data mining will be
less than through manual knowledge base creation and that the
volume of rules generated will outstrip existing expert-curated
knowledge bases. Finally, we hypothesize that the empiric basis
and inherent measurability of the rules developed through these
techniques will allow them to be more readily characterized and
validated than expert-derived rules without a similar empiric
basis.3. Methods
In our project, we used two related data mining techniques: fre-
quent item set mining and association rule mining. Frequent item
set mining is a technique for locating commonly co-occurring
items in a transaction database. Association rule mining is an
extension of frequent item set mining, which looks at the direction
of association in addition to simple co-occurrence. The two tech-
niques are closely related and complementary; in fact, the output
of frequent item set mining algorithms can be used as the input
to many association rule mining algorithms.
3.1. Frequent item set mining
Frequent item set mining, as introduced in the background Sec-
tion 2, is an important tool for assessing the co-occurrence of items
in a transactional database and, thus, for determining possible
associations among them. To describe the technique, we must
introduce some formalism. We begin with the set I, which contains
all of the items which might appear in the transaction database. In
A. Wright et al. / Journal of Biomedical Informatics 43 (2010) 891–901 893a grocery store example, I would contain all of the items available
for purchase in the store; in a clinical example, I might contain all
of the medications, procedures and laboratory tests which might
be orderable in a hospital. The next concept is the transaction Ti.
Each transaction is a set of items that occur together in some log-
ical grouping which we call a transaction. In the grocery example, a
transaction might be all the items purchased together by a cus-
tomer (e.g., the contents of their basket, which is why this frequent
item set mining is sometimes called ‘‘market basket analysis”). In
the clinical example, it might be all the orders for a patient in a par-
ticular admission (or perhaps longitudinally). Each Ti # I. We refer
to a database D, which contains all of the transactions T0 . . . Tn.
The concepts introduced thus far (item, transaction and data-
base) are needed to characterize what happened in a particular
transactional setting. However, with frequent item set mining,
our goal is to determine which items in I naturally occur together
within the database D. We call these co-occurring groups of items
item sets, and we term candidate item sets X. We deﬁne the cover
of a candidate item set X to be the set of transactions in D that con-
tain X. The support of X is deﬁned as the number of items in the
cover of X (i.e., support(X) = |cover(X)|). We should note that some-
times support is alternatively deﬁned as |cover(X)|/|D|, or the pro-
portion of transactions in D that contain X.
3.2. An example
To illustrate these concepts, it is helpful to introduce an exam-
ple. Consider ﬁve patients whom we will characterize only by their
medications and problems. These patients are shown in Fig. 1.
In this example, the set I consists of all the unique medications
and problems, and contains I = {diabetes, hypertension, insulin, lis-
inopril, metformin, multivitamin, polycystic ovarian syndrome}.
Each patient can be thought of as a transaction Ti in the clinical
database D. One can readily observe some frequent item sets that
appear to be promising. For example, the item set X = {lisinopril,
hypertension} has support of 2 (since two patients have both lisin-
opril and hypertension in their set transaction). The cover of X is
{pt 1, pt 2}. The item set {metformin, diabetes} and {insulin, diabe-
tes} also have support of 2. Patient 5 provides a possible counter-
example to this apparent association between metformin and
diabetes, however. The statistical measures we use to account for
this will be described later.
3.3. An efﬁcient algorithm
It seems, from this example at least, that frequent item set
miningmay be a useful technique for determining the relationships
between data elements. In the simple example above, one canmen-
tally identify the possible frequent item sets and compute their
support. However, when the number of items is high, frequent item
set mining poses a substantial computational challenge. Indeed,
given a set of items I, there are 2|I| candidate item sets. For a small
item set, this computation may be tractable. However, it quickly
becomes intractable when the size of the item set is large. ForPt 1: {lisinopril, multivitamin, hypertension} 
Pt 2: {insulin, metformin, lisinopril, diabetes, hypertension} 
Pt 3: {insulin, diabetes} 
Pt 4: {metformin, diabetes} 
Pt 5: {metformin, polycystic ovarian syndrome} 
Fig. 1. The medications and problems for 5 sample patients.example, a two year sample of data from the Brigham andWomen’s
Hospital (BWH) shows a total of 25,848 unique data elements re-
corded across the medication, laboratory result and problem do-
mains (this includes only coded elements – when uncoded data
elements are included the number is much higher). This means
the total candidate item set space contains 225848 = 1.055  107781
members, which is computationally intractable.
In 1993, Rakesh Agrawal, of IBM’s Almaden Research Center, de-
scribed an efﬁcient algorithm for computing the complete set of
frequent item sets with support greater than a minimum threshold
from a database [28]. This algorithm exploits a property of the sup-
port metric ﬁrst described by Agrawal: downward closure. This
property states that:
X#Y ) supportðYÞ  supportðXÞ
the property follows trivially from the fact that:
coverðYÞ# coverðXÞ
In words, it means that, given a candidate item set X, any item
set Ywhich fully contains Xmust have support less than or equal to
the support of X. In other words, if you extend the item set X by
adding an item to it, the support must either remain the same or
go down, it cannot increase.
The Apriori algorithm has four phases: initiation, joining, prun-
ing and evaluation. The algorithm begins with an initiation phase.
In this phase, all 1-item sets with support > minimum support
(minsup) are generated. These 1-item sets are frequent (because
their support > minsup) so they are added to the result. Next, all
of these 1-item sets are joined with each other to produce 2-item
sets (the joining phase). Each of these 2-item sets is evaluated to
determine whether the item set exceeds the support threshold
(the evaluation phase). If it does, it is added to the result. Next,
the 2-item sets are combined to form 3-item sets. However, from
this point, another step is added: the pruning phase. Each 3-item
set is checked to see whether it contains any 2-item sets or 1-item
sets that are not in the result set (e.g., non-frequent). The upper
bound of the support for any particular 3-item set is, by the down-
ward closure property of support, the support of its least frequent
subset. If any subset of the 3-item set is not frequent (e.g., not in
the result set), then the 3-item set itself must be non-frequent
and does not need to be evaluated. If all subsets of the 3-item set
are frequent, then we proceed to the evaluation phase.
Although a naïve algorithm that performed only the initiation,
joining and evaluation steps would work correctly, the pruning
step has two key advantages over such a naïve algorithm. First,
the evaluation space is much smaller, since many candidate item
sets are excluded during pruning (and, additionally, all supersets
of excluded item sets are also pruned, further limiting the search
space). Second, the algorithm naturally terminates when there
can be no further joining of k-item sets into k + 1-item sets that
are not all pruned. This allows the algorithm to terminate much
sooner than the naïve algorithm which must process the entire
power set of the item set before terminating.
3.4. Association rule mining
Frequent item sets, by themselves, are inherently nondirec-
tional. An item set is considered frequent if its support exceeds
the support threshold. However, some relationships between items
may have a direction. In the example given in Fig. 1, the {insulin,
diabetes} relationship is directional. This directionality is fairly
obvious clinically: almost everyone who receives insulin has diabe-
tes, but only certain people with diabetes receive insulin.
To account for this directionality, frequent item set mining is
often extended to association rule mining. An association rule is
an expression X? Y where X is an item set, Y is an item set and X
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izedby their support.We say that supportðX ! YÞ ¼ supportðX [ YÞ.
This measure, however, is symmetric (i.e., support(X Y) = sup-
port(Y? X)). In order to account for directionality, we introduce
another measure: conﬁdence. We deﬁne conﬁdenceðX ! YÞ
¼ supportðX [ YÞ=supportðXÞ. The conﬁdence is the proportion of
all transactions containingX that also containY. In our example from
Fig. 1, conﬁdence({insulin}? {diabetes}) = 100% since all patients
receiving insulin also have diabetes. However, conﬁdence({diabe-
tes}? {insulin}) = 66.7% (because one patient, pt 4, is receiving only
metformin for his diabetes).
It is important to note that the directionality inferred by associ-
ation rule mining is purely correlational. An implication X? Y,
with conﬁdence c, simply means that c% of transactions containing
X also contain Y. Such a relationship should not be construed as
implying causation without further analysis (typically beyond
association rule mining, e.g. an experiment).
3.5. Measures of Interestingness
Although association rules can be ﬁltered by their support and
conﬁdence, there are often many more potential rules produced
through these techniques than can be manually reviewed. A vari-
ety of measures of ‘‘interestingness” have been proposed which
can be used to ﬁlter these item sets and association rules [29].
In this paper, we concentrate our attention on ﬁve commonly
used and robust measures: support, conﬁdence, chi square, inter-
est (sometimes called lift) and conviction. The formulas for these
statistics are given in Fig. 2. In this ﬁgure, for a given rule
(X? Y), a represents the number of transactions in the database
containing both X and Y, b the number containing X but not Y, c
the number containing Y but not X and d the number containing
neither X nor Y.
Support and conﬁdence have already been deﬁned in this sec-
tion. The chi square statistic has its usual meaning. To compute
chisq(X? Y), one conceives of the database D as a two-by-two ta-
ble. The upper-left cell contains the number of transactions which
contain both X and Y, the upper-right the number of transactions
which contain X but not Y, the lower-left the number of transac-
tions which contain Y but not X and the lower-right the number
of transactions which contain neither X nor Y. The advantage of
the chi square statistic is that it accounts for the baseline frequency
of X and Y. Support, on the other hand, does not: association rules
may score highly simply because their members are very frequent
in the database, even if the relationship between X and Y is weak.Fig. 2. Formulation of ﬁve measures of interestingness used in the project.Interest (or lift) is another statistic which attempts to correct for
this weakness. Conﬁdence tends to rate rules highly where the
consequent (Y) is frequent. For example, if 80% of transactions in
a database contain Y, then the expected conﬁdence of any rule
X? Y is 80%, even before taking the inﬂuence of X on Y into ac-
count. The interest(X? Y) is deﬁned as the conﬁdence(X? Y) di-
vided by the proportion of all transactions that contain Y. This
scales the conﬁdence to account for the commonality (or rarity)
of Y.
The ﬁnal measure we consider is conviction, described by Brin,
Motwani, Ullman and Tsur [30]. Conviction stands out among the
other statistics because its derivation is actually grounded in error
rates (where an error is a counter example to the rule X? Y, i.e. a
transaction where X occurs but Y does not). Conviction, then, is the
ratio between the expected error rate assuming independence and
the observed error rate. Higher values indicate greater strength of
association (indeed conviction has no upper bound, and inﬁnite
conviction corresponds to the case where there were no errors ob-
served and every transaction containing X also contains Y).
3.6. Data set
We hypothesized that association rule mining would be a useful
technique for inferring relationships between medications, labora-
tory results and problems. Such relationships could then be used to
identify potential gaps in patient problem lists. In order to explore
this, we randomly selected a cohort of 100,000 patients of the Brig-
ham and Women’s Hospital. To be included in our cohort, a patient
must have been seen at least once during 2007 and 2008 and have
two or more outpatient notes in their record. We excluded patients
who had fewer than two notes because many of them may have
been seen in an acute or consultative setting and have limited
documentation.
For each of these patients, we requested and received struc-
tured problems, laboratory results and medications as stored in
our EHR system. The problems are coded using a proprietary prob-
lem terminology that is mapped to SNOMED CT [31]. Laboratory
results are coded using LOINC [32] and the result ﬁle includes
the laboratory test identiﬁer, LOINC code, numeric result, unit of
measure, text result, ﬂags and comments. Medications are coded
using a propriety medication terminology that is mapped to First
Databank and also, indirectly, to RxNorm [33]. The medication ﬁle
contains the medication, route and dose.
All data were de-identiﬁed and encrypted before being ana-
lyzed. Our protocol was reviewed and approved by the Partners
HealthCare Human Subjects Committee.
After requesting and receiving the problem, medication and lab-
oratory result data ﬁles, we prepared them for analysis. Problems
were stripped of modiﬁers and qualiﬁers, medications were simpli-
ﬁed to just the drug product (excluding route and dose) and labo-
ratory results were analyzed three ways: (1) just by unique test
(e.g., all CD4 tests would be viewed as identical, regardless of the
result), (2) by test and ﬂag (e.g., a high CD4 would be viewed as dif-
ferent from a normal or low CD4) and (3) for tests with qualitative
results (which generally lack ﬂags), by test and qualitative result
(e.g., a blood smear with the result ‘‘2 + sickle cells” would be
viewed as different from a smear with the result ‘‘normal
morphology”).
3.7. Extensions to the techniques
After a preliminary analysis, we noted two problems with con-
ventional approaches to association rule mining that were limiting
the accuracy of our results. First, we found that the associations be-
tween many anti-HIV agents and the problem HIV was lower than
expected. We traced this to the fact that some of the patients had
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both). As a result, we developed a set of problem classes, which
combined clinically related entities. These classes are described
in Appendix 1.
We also found that therewere some unexpectedly strong associ-
ations between apparently unrelated itemswhichwe believedwere
attributable to comorbidities. For example, the association rule insu-
lin? hypertension scored highly, despite the fact that insulin is
used to treat diabetes, not hypertension. However, there is strong
comorbidity between the two conditions, so this rule is likely due
to transitive association. We were unable to locate any method to
control for this in the literature. After signiﬁcant experimentation,
we devised a hold-out method. In this method, signiﬁcant prob-
lem-problem associations (i.e., comorbidities) are ﬁrst computed.
Then, whenever a candidate association is located that meets the
support and conﬁdence thresholds (we used a minimum support
of 5 and conﬁdence of 10%), we locate the comorbidities for that
problem. For each comorbidity, we repeat the analysis of the candi-
date association is repeated on the subset of patients without the
comorbid condition and evaluate the change in statistics.
Prior systems have also used transitive inference in association
rule mining; however, they used it to infer additional association
rules. For example, Narayanasamy et al. describe a text-mining
application mining Medline for associations between diseases and
genes [34]. They are interested in the situation where they locate
associations A? B and B? C, but do not ﬁnd an association A? C.
In this circumstance, they do an additional round of evaluation to
determine if A? C is also a valid association. In other words, they
employ transitive association rules as a tool for generating addi-
tional candidate associations which are not otherwise found.
We use transitive inference for the reverse problem: pruning
spurious candidate associations. Using our diabetes example, we
found the rule insulin? hypertension. To validate this candidate
association, we reviewed comorbidity data, and found a disease-
disease association: diabetes? hypertension, as well as several
other disease-disease associations with hypertension. We then
iteratively re-evaluated the insulin? hypertension rule once for
each disease comorbid with hypertension, and found that the rule
fell below our threshold when diabetic patients were excluded.
Based on this, we identiﬁed diabetes as a transitive mediator for
the spurious insulin? hypertension rule and were thus able to
automatically reduce the candidate rule set by removing the rule.
This is in contrast to the Narayanasamy method, which would ap-
ply to a situation where we identiﬁed rules insulin? diabetes and
diabetes? hypertension but did not identify the rule insu-
lin? hypertension. We would apply the method, which would
then propose insulin? hypertension for further study (candidate
generation rather than reduction).3.8. Analysis
Several different software packages were tested for computing
association rules; however, we found that they were not adequate
to perform the analyses needed. Some were unable to handle the
large volume of data or required substantial reformatting of the in-
put. Others lacked support for the statistics that we wanted to in-
clude in our analysis, and none supported (or could be easily
extended to support) our novel iterative transitive reduction tech-
nique. As a result, we developed our own analysis software which
implements the Apriori algorithm but is tuned speciﬁcally for clin-
ical data. It supports all of the statistics of interest, the iterative
transitive reduction technique and also provides for on-the-ﬂy
encryption and decryption of the datasets. The software was devel-
oped in C# and compiled using Microsoft Visual Studio 2008 for
the .NET 3.5 Common Language Runtime. All analyses were carriedout on a computer with 2 GB of memory and an Intel Core 2 Duo
L7500 processor running at 1.60 GHz.
We used the software to generate the top 500 associations for
drugs and labs with problems according to each of the ﬁve statis-
tics of interest. We limited generation to rules with a single drug
or lab in the antecedent set and a single problem in the consequent
set in order to enable gold standard evaluation. Because there is
signiﬁcant overlap in the associations selected by each statistic,
the total number of associations was less than 2500.4. Evaluation
After generating the association rules for medications, labora-
tory results, and problems, we evaluated the rules by comparing
them to a gold standard. For medications, we used the Lexi-Comp
drug knowledge base (Lexi-Comp, Inc., Hudson, Ohio), which con-
tains information including pharmacology, dosing, administration,
use and contraindications of all FDA-approved drug products. For
laboratory results, we used Mosby’s Diagnostic and Laboratory Test
Reference [35] which contains information on common laboratory
test results and their uses.
For the evaluation, we identiﬁed the top 500 medication-prob-
lem and laboratory-problem associations according to each of the
ﬁve statistics, yielding ten lists of 500 items (e.g., one list for the
top 500 medications according to support and another for the
top 500 laboratory results using chi square). We then compared
each association to the reference sources to determine whether
the association was also found in the gold standard reference
source. Because the Lexi-Comp database contains all drugs, medi-
cation-problem associations were coded as either ‘‘indicated” or
‘‘not indicated”. Mosby’s Diagnostic and Laboratory Test Reference,
however, did not contain some esoteric laboratory results (the
number of unique laboratory tests is much larger than the number
of FDA-approved medications, and we were unable to locate any
gold standard which was entirely complete). Therefore, for labora-
tory results, each identiﬁed pair was coded as ‘‘indicated”, ‘‘not
indicated” or ‘‘not found”.
Based on these comparisons, we computed an ‘‘accuracy” statis-
tic – the proportion of associations found that matched the gold
standard. Using a diagnostic testing framework, accuracy is analo-
gous to positive predictive value (or precision in an information re-
trieval framework). Our gold standards were not necessarily
complete (they did not contain all medications, all laboratory tests,
all diseases and all associations or indications), so it was not possi-
ble to calculate sensitivity and speciﬁcity, or to carry out a receiver
operating characteristic (ROC) analysis.5. Results
Data were successfully acquired for 100,000 Brigham and Wo-
men’s Hospital patients. The dataset included 272,749 coded prob-
lems, 442,658 coded medications and 11,801,068 coded laboratory
results from the EHR system. There were 1756 unique coded prob-
lems, 2128 unique medications and 1341 unique coded laboratory
results. The total size of the dataset was 762 megabytes (laboratory
test results predominated). We ran our programs on the dataset,
which took approximately nine minutes to complete (reading the
data into efﬁcient in-memory structures predominated – the actual
analysis step was very short).
5.1. Medication-problem associations
A total of 10,735 medication-problem associations with support
of at least 5 and conﬁdence of at least 10% were identiﬁed. We
characterized all of these pairs with the ﬁve statistics described
Table 1
Top 50 medication-problem associations under chi square.
Medication Problem Support Conﬁdence Chi square Interest Conviction
Cyclosporine micro (Neoral) Cardiac transplant 72 47.37% 15974.05 222.76 1.90
Ritonavir HIV/AIDSb 108 87.10% 13584.49 126.62 7.70
Tenofovir/emtricitabinea HIV/AIDSb 117 74.05% 12484.95 107.66 3.83
Multivitamin (vitamins A, D, E, K) Cystic ﬁbrosis 13 76.47% 12206.84 939.93 4.25
Atazanavir HIV/AIDSb 91 87.50% 11495.76 127.21 7.94
Efavirenz/emtricitabine/tenofovira HIV/AIDSb 77 95.06% 10576.62 138.20 20.11
Efavirenz/emtricitabine/tenofovira HIV positive 73 90.12% 10525.03 145.06 10.06
Ritonavir HIV positive 90 72.58% 10423.49 116.82 3.62
Cyclosporine micro (Neoral) Stress test 63 41.45% 10390.04 166.04 1.70
Tenofovir/emtricitabinea HIV positive 101 63.92% 10284.74 102.89 2.75
Atazanavir HIV positive 79 75.96% 9579.52 122.27 4.13
Dornase alfa Cystic ﬁbrosis 11 68.75% 9283.65 845.03 3.20
Hydroxyurea (non-oncology dose) Sickle cell anemia 13 44.83% 8502.43 655.23 1.81
Pancrelipase 20,000 units Cystic ﬁbrosis 16 41.03% 8048.56 504.26 1.69
Cyclosporine micro (Neoral) Cardiac catheterization 65 42.76% 6597.73 102.79 1.74
Clozapine Schizophreniab 39 57.35% 6352.86 164.11 2.34
Hydroxychloroquine Systemic lupus 204 23.26% 5863.47 30.02 1.29
Cyanocobalamin B12 deﬁciency 186 18.62% 5815.46 32.48 1.22
Allopurinol Gout 495 45.50% 5513.09 24.17 1.80
Tiotropium COPD 223 41.22% 5430.53 25.68 1.67
Abacavir/lamivudine HIV/AIDSb 40 93.02% 5371.03 135.24 14.23
Tiotropium COPDb 224 41.40% 5255.21 24.80 1.68
Colchicine Gout 244 42.00% 5117.07 22.31 1.69
Clozapine Schizophrenia 31 45.59% 5088.16 165.47 1.83
Latanoprost Glaucoma 218 57.07% 5044.50 24.40 2.27
Cabergoline Prolactinoma 20 24.10% 4710.94 236.94 1.32
Pentosan polysulfate Interstitial cystitis 13 44.83% 4617.13 356.52 1.81
Efavirenz HIV/AIDSb 39 81.25% 4564.53 118.12 5.30
Abacavir/lamivudine HIV positive 35 81.40% 4547.55 131.01 5.34
Methotrexate (non-oncology dose) Rheumatoid arthritis 219 38.76% 4405.36 21.50 1.60
Carbidopa/levodopaa Parkinson’sb 47 33.57% 4377.79 94.56 1.50
Mesalamine Crohns disease 54 45.38% 4373.43 82.35 1.82
Ritonavir AIDS 20 16.13% 4228.06 212.75 1.19
Griseofulvin Tinea capitis 5 21.74% 4191.79 839.78 1.28
Glatiramer Multiple sclerosis 124 34.25% 4166.33 35.02 1.51
Efavirenz HIV positive 35 72.92% 4066.94 117.37 3.67
Desmopressin nasal von Willebrand’s 7 63.64% 3876.90 555.09 2.75
Pancrelipase 16,000 units Cystic ﬁbrosis 5 62.50% 3834.74 768.21 2.66
Nephrocaps End stage renal disease 39 22.16% 3742.90 97.43 1.28
Lopinavir/Ritonavir HIV/AIDSb 40 63.49% 3641.93 92.31 2.72
Enofovir HIV/AIDSb 32 78.05% 3594.71 113.47 4.52
Carbidopa/levodopaa Parkinson’s diseaseb 40 28.57% 3555.36 90.36 1.40
Carbidopa/levodopaa Parkinson’s diseaseb 40 28.57% 3555.36 90.36 1.40
Tocopherol-dl-alpha Cardiac transplant 74 10.44% 3539.56 49.08 1.11
Azathioprine Cardiac transplant 51 14.78% 3473.72 69.52 1.17
Pyridostigmine Myasthenia gravis 10 25.64% 3451.86 346.68 1.34
Lopinavir/Ritonavir HIV positive 37 58.73% 3449.47 94.53 2.41
Calcipotriene Psoriasis 130 38.92% 3303.25 26.85 1.61
Furosemide Congestive heart failure 351 11.51% 3290.76 10.66 1.12
Tenofovir HIV positive 29 70.73% 3266.62 113.85 3.40
a Combination product.
b Problem classes.
Fig. 3. Centered moving average accuracy of the top 500 medication-problem associations according to ﬁve statistics.
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Table 2
Top 50 laboratory-problem associations under interest.
Laboratory Result Problem Support Conﬁdence Chi Square Interest Conviction
Bethesda inhibitor assay Hemophilia 7 25.00% 5906.03 845.03 1.33
vWF multimers von Willebrand’s disease 8 53.33% 3711.07 465.22 2.14
Fetal hemoglobin Sickle cell anemia 18 25.35% 6647.50 370.57 1.34
Cotinine Lung Transplant 9 18.75% 2452.46 274.06 1.23
Cotinine Cystic Fibrosis 10 20.83% 2545.07 256.07 1.26
Cotinine Pulmonary Fibrosis 9 27.27% 1997.01 223.48 1.37
Vitamin K Cystic Fibrosis 8 17.39% 1696.96 213.76 1.21
Cyclosporine level Cardiac Transplant 101 42.98% 20344.05 202.12 1.75
Tobramycin level Cystic Fibrosis 10 16.13% 1966.38 198.25 1.19
Cotinine Pulmonary Fibrosis 11 22.92% 2048.01 187.78 1.30
HHV6 type Graft vs. host disease 5 10.64% 890.30 179.79 1.12
Voriconazole level Bone marrow transplant 5 26.32% 870.16 175.71 1.36
HHV6 PCR Graft vs. host disease 5 10.20% 853.58 172.46 1.11
Respiratory syncytial virus Lung transplant 14 11.29% 2289.29 165.03 1.13
Cyclosporine level Stress test 91 38.72% 14031.15 155.13 1.63
HEP C SUPPLEMENTAL Pulmonary ﬁbrosis 9 18.37% 1339.46 150.51 1.22
Acetylcholine receptor antibodies Myasthenia gravis 7 11.11% 1039.62 150.23 1.12
Plasma hemoglobin Cytomegalovirus 5 11.90% 739.84 149.73 1.13
Bone marrow aspirate Acute myeloblastic leukemia 18 16.51% 2607.68 146.41 1.20
Vitamin A Cystic ﬁbrosis 10 11.63% 1412.69 142.92 1.13
Vitamin E Cystic ﬁbrosis 9 11.54% 1261.32 141.82 1.13
RPR titer Syphilis 27 17.20% 3709.60 138.82 1.21
HHV6 PCR Bone marrow transplant 10 20.41% 1345.92 136.26 1.25
HHV6 type Acute myeloblastic leukemia 7 14.89% 912.19 132.05 1.17
vWF:RCo assay von Willebrand’s disease 23 15.03% 2981.98 131.13 1.18
Factor VIII:C von Willebrand’s disease 23 14.84% 2943.02 129.44 1.17
MHA-TP Syphilis 27 15.98% 3443.14 128.96 1.19
HHV6 type Bone marrow transplant 9 19.15% 1135.44 127.85 1.23
HHV6 PCR Acute myeloblastic leukemia 7 14.29% 874.42 126.66 1.17
vWF antigen von Willebrand’s disease 23 14.29% 2831.95 124.61 1.17
Plasma hgb Cardiac transplant 11 26.19% 1336.82 123.17 1.35
Coccidioidomycosis Pulmonary ﬁbrosis 10 14.71% 1188.06 120.50 1.17
HBsAg neutralization assay Hepatitis B 6 42.86% 592.77 100.34 1.74
Adenovirus PCR Bone marrow transplant 8 14.81% 777.34 98.92 1.17
BK virus PCR Kidney transplant 5 12.82% 465.92 94.98 1.15
Cyclosporine level Cardiac catheterization 92 39.15% 8546.73 94.10 1.64
Rapamycin level Bone marrow transplant 34 13.99% 3127.36 93.42 1.16
Blasts Acute myeloblastic leukemia 21 10.24% 1874.69 90.82 1.11
BK viral load Kidney transplant 17 12.23% 1512.44 90.61 1.14
Epinephrine-induced plt agg (100 lm) von Willebrand’s disease 5 10.20% 436.00 89.01 1.11
Ristocetin-induced plt agglut von Willebrand’s disease 5 10.20% 436.00 89.01 1.11
Collagen-induced plt agg von Willebrand’s disease 5 10.20% 436.00 89.01 1.11
Epinephrine-induced plt agg von Willebrand’s disease 5 10.20% 436.00 89.01 1.11
Arachiodonate-induced plt agg von Willebrand’s disease 5 10.20% 436.00 89.01 1.11
FMC-7 HIV positive 246 54.67% 21467.36 87.99 2.19
Lymphogranuloma venereum ab HIV/AIDSa 9 60.00% 772.69 87.23 2.48
FMC-7 HIV/AIDSa 264 58.67% 22329.93 85.29 2.40
CD4 HIV positive 254 50.50% 20456.20 81.28 2.01
Mycophenolic acid Cardiac transplant 5 17.24% 396.53 81.08 1.21
CD4 HIV/AIDS^ 273 54.27% 21342.46 78.90 2.17
a Problem classes.
Fig. 4. Centered moving average accuracy of the top 500 laboratory-problem associations according to ﬁve statistics.
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Table 1 shows the top 50 medication-problem associations
based on the chi square statistic. A review of the table suggests
that all 50 associations are clinically valid when compared to
the gold standard, and that many of them are also very speciﬁc
(for example, a variety of anti-retroviral agents are associated
with HIV and/or AIDS – these agents are used only to treat HIV
and AIDS). Several rows bear special mention. First, some of the
problems (marked with ^) are actually problem classes (described
in Section 3 and Appendix 1). In a few cases, this causes duplicate
associations: for example, ritonavir is associated both with the
HIV/AIDS class and the problem ‘‘HIV positive”. The HIV/AIDS
class association has a higher conﬁdence (87.10%) than the HIV
positive problem association (72.58%). This is because some pa-
tients have only AIDS and not HIV on their problem list, so when
the two are combined the conﬁdence increases. It should be
noted that ritonavir is used only to treat HIV (with our without
AIDS), so the 12.90% of ritonavir-using patients with neither
HIV nor AIDS on their problem list represents an omission (acci-
dental or intentional) from those patients’ problem lists.
The pancrelipase, methotrexate and hydroxyurea associations
also merit special mention. Although we did not explicitly con-
sider dosing in our analysis, these drugs have doses imbedded
in them in the order entry system. This is designed, in the case
of methotrexate and hydroxyurea, to enable indication based dos-
ing: these drugs both have oncology uses as well as non-oncology
uses (rheumatoid arthritis for methotrexate and sickle cell disease
for hydroxyurea) with widely differing doses. Because our system
captures the indication and dose range with the order, we can
pick out associations between the non-oncology uses and speciﬁc
problems (we did not ﬁnd speciﬁc associations for these drugs in
the domain of oncology problems likely because their use in
oncology is so broad).
Fig. 3 shows the results of our gold standard evaluation. We
compared the top 500 medication-problem associations accord-
ing to each of the ﬁve statistics to the gold standard (the Lexi-
Comp drug database). Fig. 3 shows how the accuracy of the asso-
ciations decays as a function of each statistic. Chi square ap-
peared to have the best performance, consistently maintaining
accuracy throughout the top 500. Support had the worst accu-
racy, starting strong but quickly dropping to the 30%-40% accu-
racy range. Of the top 500 associations, according to the chi
square statistic, 89.2% were also found in the gold standard sug-
gesting a high level of accuracy.
We conducted an analysis of the 10.8% associations that were
adjudged incorrect. Although not seen in the top 50 medication-
problem associations, we found that many of the apparent asso-
ciations appeared to be transitive. For example, there was an
association between insulin lispro 75%/insulin lispro protamine
25% mix (Humalog Mix 75/25) and hypertension. Indeed 60.9%
of patients on this insulin preparation also had hypertension on
their problem list, and v2 = 33.20 for the association
(p < 0.0001). Although this association is strictly true (indeed,
clinically, most diabetic patients on insulin do have hyperten-
sion), insulin is not used to treat hypertension. The association
is transitive: insulin lispro? diabetes? hypertension.
To control for these transitive associations, we used the novel
iterative transitive reduction technique described in Section 3.
Our method begins with calculating problem-problem associa-
tions to locate statistical comorbidities (we found 17,951 comor-
bidity rules with support 5 and conﬁdence 10). Then, when we
locate a potential association, such as the insulin lispro? hyper-
tension association, we ﬁnd comorbidities of hypertension
(54.52% of diabetic patients in our sample have hypertension)
and repeat our analyses holding out these comorbidities one-by-one. When we re-test the insulin lispro? hypertension asso-
ciation excluding all diabetic patients, the support drops to 1
and v2 falls from 33.20 to 0.13, strongly suggesting that insulin
lispro? hypertension is transitively mediated by diabetes. When
other comorbid conditions are used in the hold-out criteria, the
chi square statistic changes very little and remains statistically
signiﬁcant.5.2. Laboratory-problem associations
As mentioned in the methods, laboratory-problem associations
were generated in three different ways: by test, by test with ﬂag
and by test with qualitative result. Using a support threshold of 5
and a conﬁdence threshold of 10%, there were 5361 associations
with the ‘‘by test” method, 8383 with the ‘‘by test with ﬂag”
method and 5795 with the ‘‘by test with qualitative result” meth-
od. Each of these methods had its own unique advantages. For
example, the mere presence of an HIV screening test means little,
but a positive result indicates a high likelihood that the patient
has HIV; so in this case, the ‘‘test with ﬂag” method would yield
the best results. By contrast, the mere presence of a CD4/CD8 ra-
tio test, regardless of the result, strongly suggests HIV because the
test is ordered almost exclusively in this population so the ‘‘by
test” method may work best. However, for a test with qualitative
results (such as a blood smear), there are no ﬂags, so the result
itself must be used, making the ‘‘by test with qualitative result”
superior.
Table 2 shows the top 50 associations using the ‘‘by test” meth-
od according to the interest statistic. The interest statistic is pre-
sented here because it had the highest accuracy (55.6% across the
top 500). We focused the analysis on the ‘‘by test” method because
our gold standard provided clear indications for each test, but
interpretation of the test results (either by reference range driven
ﬂags or qualitative results) was much more subjective. Like Table
1, the results in Table 2 appear generally accurate based on the
gold standard. The table contains a number of drug levels paired
with associated conditions, some viral and bacterial antibodies
and PCR tests that are highly speciﬁc for their associated problems,
a number of transplant-related tests and associated transplants as
well as a host of tests related to von Willebrand’s disease and a
substantial number of HIV-related tests.
Fig. 4 shows the results of our gold standard analysis. As men-
tioned in Section 3, unlike medications, where all medications
were listed in our gold standard, not all laboratory tests were listed
in our laboratory gold standard. As a result, each association iden-
tiﬁed by our techniques was coded ‘‘indicated”, ‘‘not indicated” or
‘‘not found”. The ‘‘not found” results were excluded from our anal-
ysis. The overall accuracy of the laboratory-problem associations is
not as strong as the medication-problem associations and the sta-
tistics decay more quickly. However, most of the statistics start out
with high accuracy and over the full run of 500, have about 50%
accuracy.6. Discussion
Overall, the techniques appear to have worked well and
achieved reasonable accuracy. We were able to analyze a large
amount of data in a reasonable period of time. We found that the
chi square statistic had the best general performance for medica-
tions, while the interest statistic was best for laboratory results.
The support statistic had the worst performance in both cases. This
suggests that there is no clear ‘‘best” statistic – instead, statistics
should be chosen based on individual data sets and applications
– this ﬁnding has reported elsewhere in the literature [29]. Indeed,
picking the optimal statistic is both an art and a science – some
A. Wright et al. / Journal of Biomedical Informatics 43 (2010) 891–901 899statistics may be heavily biased towards frequently occurring pat-
terns (e.g. support), while others may favor infrequent but strong
associations (e.g. interest), and still others try to balance these
tradeoffs. Likewise, picking the optimal cut-point for these statis-
tics should also be done with careful reference to both the data
and application. For some applications, the cost of a false positive
(incorrectly inferring a problem the patient does not have) may
be very high (e.g. automated initiation of treatment protocol),
while for others, the cost of a false negative (failing to infer a prob-
lem that is present) may predominate (e.g. identifying potential
patients for a research study, where representativeness is impor-
tant and the researcher will conﬁrm potential diagnoses).
A potential use of the medication-problem associations and lab-
oratory-problem associations identiﬁed by these techniques is
identifying and rectifying gaps in problems lists. The fact that the
associations were nearly 90% accurate for medications and 50%
accurate for problems suggests that, with some appropriate man-
ual review, one could consider implementing them as rules in a
clinical information system. In both cases, the results appeared to
have reasonable positive predictive value, which would be impor-
tant for any clinical decision support system.
6.1. Comparison to other techniques
There are alternatives to using data mining to determine rela-
tionships between medications, laboratory results and problems.
One alternative is a knowledge-based technique, where human ex-
perts determine associations between medications, laboratory re-
sults and problem. The techniques used in this study have some
advantages over alternative knowledge-based techniques that
may be manually intensive and costly.
First, our techniques offer advantages in terms of speed and
time. It took about nine minutes to process the entire data set
and generate thousands of medication-problem and laboratory-
problem associations. Having experts do the same thing would
have been much more time-consuming. Our automatically gener-
ated associations may require manual review; however, such
review is likely to be more efﬁcient than creating rules from
scratch.
Second, our technique has advantages in terms of currency: an
expert-curated knowledge base must be constantly updated to ac-
count for new clinical knowledge and new clinical entities (such as
novel drugs); this knowledge management task is very large and
perfect currency may be nearly impossible. Our techniques, by
contrast, can be repeated as often as is desired, and the incremen-
tal cost is negligible.
Third, our techniques may better reﬂect current practice pat-
terns. For example, some drug knowledge bases (such as the FDA’s
SPL project [36]) reﬂect only approved uses of medications, but
these techniques can infer both on- and off-label uses.
Fourth, these techniques include inherent metrics. For example,
an expert might state that ‘‘metformin is used to treat diabetes”
but assigning a certainty to this statement is difﬁcult. Our tech-
niques indicate that this association held only 70.6% of the time.
Review of the 29.4% of patients on metformin without diabetes
also indicates that a greater-than-expected proportion of them
have polycystic ovarian syndrome or breast cancer (alternative
uses of metformin).
The ﬁnal advantage of our technique relates to terminologies.
Because our techniques operate directly on EHR data, the associa-
tions we ﬁnd are automatically coded using the same terminolo-
gies as the EHR. However, implementing an expert statement like
‘‘metformin is associated with diabetes” requires manual mapping
of the metformin and diabetes concepts. This mapping is also error
prone. In addition to plain metformin, a variety of metformin-con-
taining products are also available (e.g., combined with glyburideor rosiglitazone, or an extended release formulation). All of these
products are automatically ﬂagged as related to diabetes by our
techniques, but a knowledge engineer would have to know about
these products and manually associate them.
Though these advantages are important, there are also some
disadvantages of these techniques when compared with knowl-
edge-based techniques. First, these techniques work best for
frequently occurring combinations. There are likely many medica-
tions, problems and laboratory tests which are used so
infrequently that they could not be identiﬁed by our methods de-
spite being strongly related. Knowledge-based techniques, given
sufﬁcient resources, would be able to identify such relationships
(e.g., through substantial literature review).
Second, some of the relationships found in our analysis are only
indirect. While it is, for example, strictly true that insulin is
strongly associated with hypertension, the association is not direct,
and a knowledge base that posited that ‘‘insulin is used to treat
hypertension” would be incorrect – an error unlikely to be made
with a knowledge-based mechanism. This disadvantage may, how-
ever, also be an advantage in certain settings: if one were attempt-
ing to locate hypertensive patients, it might be reasonable to
screen insulin users despite the lack of a direct relationship.
The ﬁnal disadvantage is the dual of the third advantage: the
techniques reﬂect current practice patterns. To the extent that
these practice patterns may be less-than-ideal, or at least not en-
tirely evidence-based, any application of these techniques that
tends to perpetuate these patterns may have undesirable results.
Knowledge-based techniques, particularly those grounded in evi-
dence, are less likely to perpetuate sub-optimal practice patterns
and may, in fact, be useful for correcting such sub-optimal pat-
terns. However, at the same time, these techniques may be power-
ful tools for identifying and characterizing practice patterns
(positive or negative), so that sub-optimal practice might be
remediated.
Given this balance of advantages and disadvantages, it is also
reasonable to imagine that association rule mining might be used
in conjunction with knowledge-based techniques to create maxi-
mally effective decision support systems. For example, experts
might be presented with automatically inferred association rules,
and could validate (or reject them), or simply use them as another
input to their knowledge base development process. Alternatively,
expert-generated content could be retrospectively validated
against association rules and other automatically derived mea-
sured, allowing the content to be characterized, and ﬁring rates
and accuracy to be predicted before the content goes live. Indeed,
all of these approaches could be combined, iteratively, to create a
more data-driven, efﬁcient and measurable expert knowledge base
development process.7. Limitations
The techniques used and results have some limitations. First
and foremost, this was a single-site study, and our site has fairly
advanced clinical systems with good uptake. In a setting with less
automation, lower utilization of clinical systems, or less availabil-
ity of structured data, the techniques might not be as successful.
We do, however, believe that the methods are highly generalizable
and that similar analyses could be carried out at other sites with
similar results.
Second, we limited our analysis to three data types (problems,
medications and laboratory results), and only to structured infor-
mation. There may be additional information available only
through other data types that were not included (such as unstruc-
tured free text information, or procedure histories) and could be
used to validate or complement ﬁndings.
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dard. This allows us to measure the accuracy of our techniques
but only enables us to speculate about their utility. Since the ulti-
mate goal of these techniques is to identify and help remediate po-
tential gaps in clinical problem lists, an experimental evaluation
with an effector arm, such as a system which alerts physicians to
probable gaps and invites them to correct them, would allow for
more deﬁnitive assessment of the techniques’ practical utility.8. Next steps
One obvious next step to extend this work is the addition of fur-
ther structured data types. For example, procedures may be strong
predictors of problems (e.g., CABG for CAD), as might certain visit
types or providers (e.g., a patient who visits a mesothelioma clinic
likely has mesothelioma, and a patient who visits a urologist who
does only TURP likely has BPH). Reliable coded data for these data
elements was not readily available to us; however, we hope to ac-
quire and analyze such data in the future.
We also plan to extend our work to consider non-structured
data, such as progress notes, radiology reports and operative notes.
We believe that these data sources may contain rich predictive
information, which is not always available in structured form.
For example, the ejection fraction from an echocardiography report
may powerfully indicate congestive heart failure, while the indica-
tion listed in an operative note might allude to a condition that the
patient was treated for but might not be documented on the prob-
lem list. We have conducted a small feasibility test of these meth-
ods and the results appear intriguing. For example, our association
rule mining strategy applied to outpatient notes found that the
word ‘‘diabetes” in a patient note was not very strongly predictive
of having diabetes, largely because of phrases like ‘‘will screen for
diabetes”, ‘‘no diabetes” or ‘‘family history of diabetes”. However,
the words ‘‘strips”, ‘‘juice” and ‘‘Joslin” (a local diabetes center)
were strongly associated with having diabetes. Although these
associations make sense in retrospect, we might not have thought
of them prospectively.
Further, there may be some value in attempting to locate larger
association rules (i.e., rules with more than one antecedent or con-
sequent). These associations may improve the speciﬁcity of rules in
ways that are impossible with a single data element. For example,
as discussed above, the drug metformin was associated with diabe-
tes in our dataset and this is its primary indication; however, it is
also used in the treatment of polycystic ovarian syndrome, so the
association between metformin and diabetes is likely to have some
false positives. However, adding laboratory information (e.g. the
patient’s last HbA1c value) to the antecedent set of the association
might result in higher conﬁdence (and accuracy under gold stan-
dard review). This extension would be quite powerful; however,
it is challenging for two reasons: ﬁrst, it would be considerably
harder to ﬁnd a gold standard – in our evaluation, we used refer-
ence sources for medication and laboratory result indications – a
similar evaluation of implications involving combinations of multi-
ple drugs or lab results with a single or multiple problems would
require a more sophisticated reference source to sue as the gold
standard (we are not aware that one exists). Further, when the
Apriori algorithm is used to generate rules with large antecedent
and consequent sets, the results can be ‘‘noisy”, containing various
trivial combinations and supersets of meaningful rules.
As a further extension of the methods, there likewise may be
value in locating unknown associations, such as unexpected prob-
lem-medication linkages that could be signs of adverse drug
events, or unexpected laboratory-problem associations which
may be signs of potential new indications for a test. These are cur-
rently counted as ‘‘false positives” in our analysis; however, someof them may represent potentially interesting new hypotheses for
more detailed investigation.
In addition to these next steps that are focused on extensions of
our methods, we have also begun exploring its potential applica-
tion. We are in the process of developing an intervention within
our electronic health record system that will use the rules gener-
ated in this study to bring potential problem list gaps to the atten-
tion of providers and help them address these gaps. Such an
intervention could have the potential to improve quality and
safety as well as to enable better decision support and quality
measurement.
9. Conclusion
Overall, the data mining methods described in this paper ap-
peared to produce results with reasonable accuracy. A variety of
‘‘interesting” associations between medications and problems
and laboratory results and problems were identiﬁed and described
and the accuracy of these associations was veriﬁed through com-
parison with a gold standard. Further, if these methods can be ex-
tended and applied, they may have utility for improving problem
list completeness and accuracy which may, in turn, have important
beneﬁts for patient care.
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